Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
This article was originally published in The Pink Sheet Daily
Executive Summary
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.